Literature DB >> 16830889

Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.

Shihomi Sakyo1, Haruyoshi Tomita, Koichi Tanimoto, Shuhei Fujimoto, Yasuyoshi Ike.   

Abstract

The potencies of the carbapenems; doripenem (DRPM), meropenem (MEPM) and imipenem (IPM) in preventing the emergence of carbapenem-resistant mutants were examined in Pseudomonas aeruginosa strains. The carbapenems predominantly selected carbapenem-resistant mutants or carbapenem mutants with reduced susceptibilities that were specifically resistant to carbapenems and had arisen as a result of the reduced level of expression of the outer membrane protein with a molecular weight of about 48,000 (OprD). The potency of carbapenems in preventing the growth of the mutants differed for DRPM, MEPM and IPM. The isolation frequency of the mutant was examined on agar plates containing each of the carbapenems at a concentration of 1/2 or 1/4 MIC of each carbapenem for that mutant. Mutants were not selected on agar containing DRPM at a frequency of greater than 10(-9) per cell per generation, whereas mutants of each strain were selected on agar containing MEPM or IPM at frequencies of 10(-7) to 10(-9) per cell per generation. The drug concentrations and the drug concentration range for the selective increase of carbapenem resistant mutants in the broth culture containing each carbapenem differed for each carbapenem. DRPM exhibited both the lowest drug concentration and the narrowest range of drug concentration for selection of the carbapenem-resistant mutants. The results shown in this report indicated that DRPM exhibited the greatest ability to prevent the emergence of the mutant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830889     DOI: 10.1038/ja.2006.31

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  23 in total

1.  Evaluation of phenotypic detection methods for metallo-β-lactamases (MBLs) in clinical isolates of Pseudomonas aeruginosa.

Authors:  S Peter; A Lacher; M Marschal; F Hölzl; M Buhl; I Autenrieth; M Kaase; M Willmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-23       Impact factor: 3.267

2.  Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.

Authors:  C Betriu; M Gómez; F López-Fabal; E Culebras; I Rodríguez-Avial; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

3.  Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; Jovan Jacob; Hanna E Sidjabat; David L Paterson; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

4.  Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.

Authors:  Susumu Tazuma; Yoshinori Igarashi; Kazuo Inui; Hirotaka Ohara; Toshio Tsuyuguchi; Shomei Ryozawa
Journal:  J Gastroenterol       Date:  2014-05-03       Impact factor: 7.527

5.  Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.

Authors:  M R Mueller; M K Hayden; S K Fridkin; D K Warren; L Phillips; K Lolans; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

6.  Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.

Authors:  Koichi Tanimoto; Haruyoshi Tomita; Shuhei Fujimoto; Katsuko Okuzumi; Yasuyoshi Ike
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

7.  Doripenem (Doribax): the newest addition to the carbapenems.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

8.  In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 9.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.